What is limited scleroderma (limited cutaneous systemic sclerosis)?

What is Limited Scleroderma (Limited Cutaneous Systemic Sclerosis)?

Limited cutaneous systemic sclerosis (lcSSc) is a subtype of systemic sclerosis characterized by skin fibrosis restricted to areas distal to the elbows and/or knees, without truncal involvement, though facial and neck skin thickening may occur. 1

Disease Definition and Classification

Limited cutaneous SSc represents the most common subset of systemic sclerosis, a rare autoimmune connective tissue disease with an estimated prevalence of 30-120 cases per million 1. The disease is fundamentally characterized by:

• Skin involvement pattern: Fibrosis confined to hands, forearms, feet, lower legs, face, and neck—specifically distal to elbows and knees without trunk involvement 1
• Underlying pathophysiology: Autoimmunity, vasculopathy, and progressive fibrosis 1
• Historical terminology: Previously known as CREST syndrome (Calcinosis, Raynaud's phenomenon, Esophageal dysmotility, Sclerodactyly, Telangiectasia) 2, 3

Clinical Presentation and Natural History

Typical Disease Course

The disease typically follows a more indolent course than diffuse cutaneous SSc, often beginning with years of isolated Raynaud's phenomenon before other manifestations appear 3. Key distinguishing features include:

• Raynaud's phenomenon: Present in nearly all patients, frequently preceding other symptoms by years 1, 3
• Skin progression: Remarkably stable over time—more than 80% of lcSSc patients have changes of less than ±4 units on the modified Rodnan skin score at 12,24, and 36-month follow-up 4
• Pace of disease: Much slower progression compared to diffuse cutaneous SSc 3

Common Manifestations

The disease affects multiple organ systems with varying frequency:

Vascular manifestations:

• Digital ulcers occur in approximately 50% of patients 1
• Telangiectasias on skin and mucous membranes 5
• Pulmonary arterial hypertension (a life-threatening complication that develops more commonly in lcSSc than diffuse disease) 3

Gastrointestinal involvement:

• Affects nearly 90% of patients 1
• Esophageal dysmotility is most common 1, 3
• Small intestine hypomotility can cause life-threatening complications 3
• Only 8% present with severe involvement, but malnutrition represents the leading cause of GI-related mortality 1

Pulmonary complications:

• Interstitial lung disease (ILD) occurs in 40-75% based on lung function changes 1
• Critically, ILD progression in lcSSc is very similar to diffuse cutaneous SSc, with FVC changes over time being nearly identical between subsets 4
• Progressive ILD occurs in 15-18% of patients 1

Other manifestations:

• Inflammatory arthritis
• Calcinosis
• Myopathy
• Sicca symptoms
• Cardiomyopathy 1

Diagnostic Considerations

Antibody Profile

Anticentromere antibodies are characteristically positive in limited cutaneous SSc 6, distinguishing it from diffuse disease which typically shows anti-topoisomerase I (Scl-70) or anti-RNA polymerase III antibodies.

Capillaroscopy

Nail fold capillaroscopy reveals characteristic SSc-pattern abnormalities including capillary dilation and avascular areas 2.

Critical Clinical Pitfalls

The lcSSc Conundrum

A major pitfall is assuming limited cutaneous SSc is uniformly "mild" disease—this is dangerously incorrect 1, 4, 7. While skin involvement remains stable, internal organ complications can be severe and life-threatening:

• Pulmonary arterial hypertension develops more frequently in lcSSc and carries significant mortality risk 3
• ILD can be as progressive as in diffuse disease 4
• Small bowel involvement can lead to severe malnutrition 3

Treatment Gap

Appropriate treatment for patients with early limited cutaneous SSc remains unknown, and further research is urgently needed 1. This represents a significant evidence gap, as:

• Most clinical trials focus exclusively on diffuse cutaneous SSc 7
• Current guidelines acknowledge uncertainty about optimal management 1
• Reliance on skin subset classification alone is insufficient to guide treatment decisions 7

Screening Requirements

Given the potential for serious organ involvement despite limited skin disease, systematic screening is essential:

Mandatory screening:

• Pulmonary arterial hypertension: Echocardiography, pulmonary function testing (especially diffusing capacity), NT-proBNP, 6-minute walk distance 1
• Interstitial lung disease: History, physical examination, chest radiography, pulmonary function testing, high-resolution CT when appropriate 1
• Digital ulcers: Regular examination, as they occur in approximately 50% of patients 1

Risk stratification for PAH:

• Longer disease duration
• Older age
• Low diffusing capacity 1

Prognosis and Disease Trajectory

Limited cutaneous SSc generally has better overall prognosis than diffuse disease, but this should not lead to complacency 3. The disease trajectory includes:

• Prolonged Raynaud's phenomenon phase (often years)
• Gradual development of skin thickening limited to distal extremities
• Stable skin disease over time in most patients 4
• Risk of late-onset severe complications, particularly PAH and progressive ILD
• Potential overlap with other connective tissue diseases including Sjögren syndrome 5

The distinction between lcSSc and a related entity called "SSc sine scleroderma" (1.5-8% of cases) is important—these patients lack definite skin involvement but develop major internal organ complications and often follow a trajectory similar to lcSSc 1.